Danahervs.Revvity
DHR vs RVTY · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Danaher is about 11× larger than Revvity by market cap; Danaher trades at the lower P/E (38.1 vs 52.6); year to date, Revvity leads (+16.1% vs −13.0%).
Side by side
| DHR | RVTY | |
|---|---|---|
| Market cap | $141B | $12.6B |
| Price | $199.05 | $112.29 |
| Today | +1.6% | −0.6% |
| Return YTD | −13.0% | +16.1% |
| Return 1Y | −3.1% | +9.7% |
| P/E | 38.1 | 52.6 |
| P/S | 5.7 | 4.3 |
| P/B | 2.7 | 1.8 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
DanaherDHR
American group focused on life science and diagnostics — bioprocessing (Cytiva), molecular diagnostics and laboratory solutions.
Full DHR profile →RevvityRVTY
Life science tools and diagnostics across newborn screening and research.
Full RVTY profile →More comparisons in Life science tools
See where DHR and RVTY sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →